Últimas noticias sobre Insulet (NASDAQ:PODD) Bolsa

Insulet

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

News

Short Ideas

Insider Trades

Markets

Trading Ideas

INTU

PODD

UPST

Este miércoles, el Nasdaq 100 cerró con un aumento de más de 400 puntos. Mientras tanto, los inversores se centraron en algunas operaciones destacadas por parte de directivos de las compañías.



Cuando los insiders

Upstart, Insulet y otras 2 acciones cuyos insiders están vendiendo

Insulet Corp

Analysts' ratings for Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) over the last quarter vary from bullish to bearish, as provided by 9 analysts.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $260.22, a high estimate of $300.00, and a low estimate of $220.00. Witnessing a positive shift, the current average has risen by 11.92% from the previous average price target of $232.50.
<img src="https://www.benzinga.com/files/images/story/2024/1730908849_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Insulet by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$269.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$223.00</td>
<td>$211.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Insulet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Insulet's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insulet analyst ratings.</a>
<h2>About Insulet</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>Understanding the Numbers: Insulet's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Insulet's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 23.2%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Insulet's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 38.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 21.08%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Insulet's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.85%, the company showcases efficient use of assets and strong financial health.
Debt Management: Insulet's debt-to-equity ratio surpasses industry norms, standing at 1.4. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

9 Analysts Have This To Say About Insulet

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d94a96b85e930001fd9dd4/kevin-dede">HC Wainwright &amp; Co. analyst Kevin Dede</a> initiated coverage on BitFuFu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) with a Buy rating and announced a price target of $7. BitFuFu shares closed at $4.57 on Tuesday. <a href="https://www.benzinga.com/quote/FUFU/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst David Katz initiated coverage on Ryman Hospitality Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHP#NYSE">RHP</a>) with a Buy rating and announced a price target of $130. Ryman Hospitality shares closed at $108.30 on Tuesday. <a href="https://www.benzinga.com/quote/RHP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61826cd080db050001bbb18a/jiong-shao">Barclays analyst Jiong Shao</a> initiated coverage on Vipshop Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) with an Overweight rating and announced a price target of $19. Vipshop shares closed at $14.58 on Tuesday. <a href="https://www.benzinga.com/quote/VIPS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wells Fargo analyst Gary Mobley initiated coverage on Rambus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMBS#NASDAQ">RMBS</a>) with an Overweight rating and announced a price target of $62. Rambus shares closed at $50.26 on Tuesday. <a href="https://www.benzinga.com/quote/RMBS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Bernstein analyst Lee Hambright initiated coverage on Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with an Outperform rating and announced a price target of $300. Insulet shares closed at $241.32 on Tuesday. <a href="https://www.benzinga.com/quote/PODD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying PODD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="582" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-1024x582.png" alt="" class="wp-image-632774" style="width:633px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-1024x582.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51-768x437.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/06083542/image-51.png 1178w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41744659/jim-cramer-says-he-cant-recommend-this-major-automaker-ceva-is-way-too-high">Jim Cramer Says He Can&#8217;t Recommend This Major Automaker, Ceva Is &#8216;Way Too High&#8217;</a></li>
</ul>

Initiation

Pre-Market Outlook

FUFU

RMBS

VIPS

This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Bernstein analyst Lee Hambright initiates coverage on Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Outperform rating and announces Price Target of $300.

Price Target

Bernstein Initiates Coverage On Insulet with Outperform Rating, Announces Price Target of $300

Retail Sales

Insulet Corporation Announced The Full Market Release Of The Omnipod 5 App For iPhone

<a href="https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions" title="https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions">https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions</a>

AAPL

DXCM

'Apple Staff Tests Blood-Sugar App In Sign Of Health Ambitions' - Bloomberg News

Insulet's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NYSE">PODD</a>) short percent of float has fallen 7.37% since its last report. The company recently reported that it has 2.77 million shares sold short, which is 5.28% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.87 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Insulet Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729868425_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Insulet has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Insulet's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Insulet's peer group average for short interest as a percentage of float is 3.92%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

(PODD) - Analyzing Insulet's Short Interest

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 10 years by 7.86% on an annualized basis producing an average annual return of 19.18%. Currently, Insulet has a market capitalization of $16.55 billion. 
Buying $1000 In PODD: If an investor had bought $1000 of PODD stock 10 years ago, it would be worth $5,810.02 today based on a price of $236.00 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729805415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Insulet 10 Years Ago Would Be Worth Today

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 10 years by 8.03% on an annualized basis producing an average annual return of 19.64%. Currently, Insulet has a market capitalization of $16.22 billion. 
Buying $100 In PODD: If an investor had bought $100 of PODD stock 10 years ago, it would be worth $619.45 today based on a price of $231.32 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729006218_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have $600 Today

Ratings for Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) were provided by 9 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $252.89, a high estimate of $285.00, and a low estimate of $220.00. This current average has increased by 8.69% from the previous average price target of $232.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1728936070_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Insulet among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$260.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$275.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$269.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$223.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$234.00</td>
<td>$234.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Insulet. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Insulet's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Insulet's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insulet analyst ratings.</a>
<h2>Delving into Insulet's Background</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>A Deep Dive into Insulet's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining Insulet's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 23.2% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Insulet's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 38.61% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Insulet's ROE excels beyond industry benchmarks, reaching 21.08%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 6.85%, the company showcases effective utilization of assets.
Debt Management: Insulet's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.4, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Insulet

Raymond James analyst Jayson Bedford maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Outperform and raises the price target from $213 to $260.

Raymond James Maintains Outperform on Insulet, Raises Price Target to $260

BTIG analyst Marie Thibault maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $250 to $260.

BTIG Maintains Buy on Insulet, Raises Price Target to $260

Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $250 to $275.

Citigroup Maintains Buy on Insulet, Raises Price Target to $275

Canaccord Genuity analyst William Plovanic maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Buy and raises the price target from $236 to $269.

Canaccord Genuity Maintains Buy on Insulet, Raises Price Target to $269

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) has outperformed the market over the past 15 years by 10.71% on an annualized basis producing an average annual return of 22.61%. Currently, Insulet has a market capitalization of $16.75 billion. 
Buying $100 In PODD: If an investor had bought $100 of PODD stock 15 years ago, it would be worth $2,138.90 today based on a price of $238.91 for PODD at the time of writing.
<h3>Insulet's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727204416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today

Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) underwent analysis by 5 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Insulet, presenting an average target of $242.4, a high estimate of $285.00, and a low estimate of $220.00. This upward trend is evident, with the current average reflecting a 5.85% increase from the previous average price target of $229.00.
<img src="https://www.benzinga.com/files/images/story/2024/1726599627_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Insulet among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$285.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$220.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$250.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Matthew Taylor</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$223.00</td>
<td>$211.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$234.00</td>
<td>$234.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Insulet. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Insulet compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Insulet's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Insulet's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/PODD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Insulet analyst ratings.</a>
<h2>Delving into Insulet's Background</h2>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>Breaking Down Insulet's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Insulet's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 23.2%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Insulet's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 38.61%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Insulet's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.08% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Insulet's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 6.85%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.4, Insulet faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Insulet's Future

WIIM

Insulet shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $230 to $285.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a>
<ul>
<li>Needham cut the price target for Immunocore Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMCR#NASDAQ">IMCR</a>) from $81 to $78. Needham analyst Gil Blum maintained a Buy rating. Immunocore shares fell 1.6% to close at $33.00 on Monday. <a href="https://www.benzinga.com/quote/IMCR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird raised the price target for Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from $41 to $45. Baird analyst Vikram Kesavabhotla maintained an Outperform rating. Doximity shares rose 0.3% to close at $39.44 on Monday. <a href="https://www.benzinga.com/quote/docs/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities boosted GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) price target from $200 to $300. B of A Securities analyst Andrew Obin upgraded the stock from Neutral to Buy. GE Vernova shares rose 1.9% to close at $229.93 on Monday. <a href="https://www.benzinga.com/quote/gev/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut Adecoagro S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGRO#NYSE">AGRO</a>) price target from $14.5 to $12.5. Morgan Stanley analyst Javier Martinez downgraded the stock from Overweight to Equal-Weight. Adecoagro shares fell 0.2% to close at $11.55 on Monday. <a href="https://www.benzinga.com/quote/agro/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Bernstein slashed the price target for Airbnb, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) from $174 to $155. Bernstein analyst Richard Clarke maintained an Outperform rating. Airbnb fell 0.2% to close at $117.55 on Monday. <a href="https://www.benzinga.com/quote/abnb/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) price target from $230 to $285. Piper Sandler analyst Matt O&#8217;Brien maintained an Overweight rating. Insulet shares rose 0.01% to close at $233.89 on Monday. <a href="https://www.benzinga.com/quote/podd/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel cut BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) price target from $115 to $87. Stifel analyst Paul Matteis maintained a Buy rating. BioMarin Pharmaceutical shares fell 17.7% to close at $69.86 on Monday. <a href="https://www.benzinga.com/quote/bmrn/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Cowen cut the price target for Topgolf Callaway Brands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MODG#NYSE">MODG</a>) from $13 to $10. TD Cowen analyst John Kernan maintained a Hold rating. Topgolf Callaway Brands shares rose 2% to close at $10.40 on Monday. <a href="https://www.benzinga.com/quote/modg/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Stifel slashed Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) price target from $135 to $130. Stifel analyst Matthew Sheerin maintained a Buy rating. Jabil shares fell 0.2% to close at $105.72 on Monday. <a href="https://www.benzinga.com/quote/jbl/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B. Riley Securities raised Alcoa Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AA#NYSE">AA</a>) price target from $37 to $41. B. Riley Securities analyst Lucas Pipes maintained a Neutral rating. Alcoa shares rose 6.1% to close at $34.50 on Monday. <a href="https://www.benzinga.com/quote/aa/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying GEV stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="481" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-1024x481.png" alt="" class="wp-image-551787" style="width:592px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-1024x481.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-300x141.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132-768x361.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/17085859/image-132.png 1322w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40896687/how-to-earn-500-a-month-from-fedex-stock-ahead-of-q1-earnings">How To Earn $500 A Month From FedEx Stock Ahead Of Q1 Earnings</a></li>
</ul>

ABNB

AGRO

BMRN

DOCS

IMCR

MODG

GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday

Piper Sandler analyst Matt O'Brien maintains Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) with a Overweight and raises the price target from $230 to $285.

Piper Sandler Maintains Overweight on Insulet, Raises Price Target to $285

In a new SEC filing on September 12, it was revealed that Hopfield, Board Member at Insulet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), executed a significant exercise of company stock options.
What Happened: Hopfield, Board Member at Insulet, made a strategic move by exercising stock options for 7,628 shares of PODD as detailed in a Form 4 filing on Thursday with the <a href="https://www.sec.gov/Archives/edgar/data/0001145197/000112760224023843//Archives/edgar/data/1145197/000112760224023843/0001127602-24-023843-index.htm">U.S. Securities and Exchange Commission</a>. The transaction value amounted to $1,533,151.
The Friday morning market activity shows Insulet shares up by 0.18%, trading at $230.86. This implies a total value of $1,533,151 for Hopfield's 7,628 shares.
<h3>All You Need to Know About Insulet</h3>
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
<h3>Unraveling the Financial Story of Insulet</h3>
Revenue Growth: Insulet's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 23.2%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 67.74%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Insulet's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 2.69.
</li>
</ul>
Debt Management: Insulet's debt-to-equity ratio stands notably higher than the industry average, reaching 1.4. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 41.68 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 9.29 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 43.84, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Emphasizing the importance of a comprehensive approach, considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>A Closer Look at Important Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001145197">Check Out The Full List Of Insulet's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Jessica Hopfield At Insulet Decides to Exercises Options Worth $1.53M

The Nasdaq 100 closed higher by over 400 points during Wednesday's session. Investors, meanwhile, focused on some notable insider trades.
When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision.
Below is a look at a few recent notable insider sales. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/">Benzinga&#8217;s insider transactions</a> platform.
<h3 class="wp-block-heading">Upstart Holdings</h3>
<ul>
<li>The Trade: Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) CFO Sanjay Datta <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 1,500 shares</a> at an average price of $34.85. The insider received around $52,275 from selling those shares.</li>
<li>What's Happening: On Aug. 20, JP Morgan analyst Reginald Smith maintained Upstart with an Underweight and raised the price target from $27 to $30.</li>
<li>What Upstart Does: Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform.</li>
</ul>
<h3 class="wp-block-heading">Zillow Group</h3>
<ul>
<li>The Trade: Zillow Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZG#NASDAQ">ZG</a>) President, Zillow Susan Daimler <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 6,031 shares</a> at an average price of $54.16. The insider received around $326,658 from selling those shares.</li>
<li>What's Happening: On Sept. 6, JMP Securities analyst Nicholas Jones reiterated Zillow with a Market Outperform and maintained a $62 price target.</li>
<li>What Zillow Group Does: Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease.</li>
</ul>
<h3 class="wp-block-heading">Intuit</h3>
<ul>
<li>The Trade: Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) EVP, Chief Technology Officer Alex G. Balazs <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 2,941 shares</a> at an average price of $628.76. The insider received around $1.85 million from selling those shares.</li>
<li>What's Happening: On Aug. 22, Intuit reported better-than-expected fourth-quarter financial results and issued FY25 EPS guidance above estimates. Also, the company approved a new $3 billion repurchase authorization.</li>
<li>What Intuit Does: Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte).</li>
</ul>
<h3 class="wp-block-heading">Insulet</h3>
<ul>
<li>The Trade: Insulet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>) Director Timothy J Scannell <a href="https://www.benzinga.com/sec/insider-trades/">sold a total of 5,000 shares</a> at an average price of $225.84. The insider received around $1.1 million from selling those shares.</li>
<li>What's Happening: On Aug. 26, Insulet said its Omnipod is now indicated for use by people with type 2 diabetes in the US..</li>
<li>What Insulet Does: Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use.</li>
</ul>
Check This Out:<a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well"> </a>
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well">Jim Cramer: &#8216;Not The Time To Own Oil,&#8217; When Asked About Exxon Mobil; Says IBM Is &#8216;Performing Well&#8217;</a></li>
</ul>

Upstart, Insulet And 2 Other Stocks Executives Are Selling

Fidelity Select Health Care Portfolio Q2 2024 Review

Piper Sandler Sticks to Its Buy Rating for Insulet (PODD)

BDX upped to buy by Citi, TNDM put on Negative Catalyst Watch

Medtronic issues recall for MiniMed insulin pumps over battery issues

ClearBridge Growth Strategy Q3 2024 Commentary

Jefferies' updated 'Franchise picks': CPAY, KVUE, SAIA, PFGC

Goldman's High Growth Investment ratio stocks: EA, AMZN, FANG, etc

Apple (AAPL) (APPL) tested an app this year to help people with prediabetes manage their food intake and make lifestyle changes, Mark Gurman of Blo...

Apple tested blood-sugar app, does not plan to release, Bloomberg says

Bernstein initiated coverage of Insulet (PODD) with an Outperform rating and $300 price target Innovation is driving accelerated insulin pump marke...

Insulet initiated with an Outperform at Bernstein

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Five Below downgraded, Snowflake upgraded: Wall Street's top analyst calls

ADSK

ALNY

AMGN

AMZN

ARDT

ARES

ARGX

AVGO

AXON

BIIB

BLDR

BMYMP

CDNS

CFCV

CPAY

CRWD

CTAS

DGEAF

DKNG

DLTR

EBAY

ETSY

EXAS

FANG

FFIV

FIVE

FSLR

GDDY

GEHC

GKOS

GLBE

GOOGL

GRMN

HUBS

INCY

INFR

INSP

INTC

KEYS

KVUE

LRGE

MASI

MRNA

MSCI

MSFT

MTCH

NCLH

NONOF

NTAP

ORCL

OSCR

PACS

PFGC

PINS

PLTR

PRCT

QCOM

REGN

SAIA

SBUX

SMCI

SNOW

SNPS

STAG

TNDM

TRMB

UBER

VEEV

VRTX

WOLF

YLDE

ZBRA

Press Releases

Insulet Reports Preliminary Second Quarter 2024 Revenue Results

Insulet Reports Second Quarter 2024 Revenue Increase of 23% Year-Over-Year

Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia

Insulet to Present at Upcoming Investor Conferences

Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024

Entertainment

General

National Campaign Launches to Combat Diabetes Stigma Using Comedy

Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors

Omnipod® 5 App for iPhone® Now Fully Available in the United States

Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November

Comments

Insulet

Noticias

Últimas noticias sobre Insulet (NASDAQ:PODD) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL